Figure 5: Evaluation of hnRNPD overexpression as a prognostic marker for OSCC. (A)Evaluation of nuclear hnRNPD as a prognostic marker. Kaplan–Meier estimation of recurrence-free survival (RFS; no recurrence / metastasis) in OSCC patients showing nuclear immunostaining of hnRNPD was 15 months as compared to 69 months for the patients showing low scores for nuclear hnRNPD immunostaining (p = 0.013). (B)Kaplan–Meier estimation of recurrence-free survival, in node negative OSCC patients showing nuclear immunostaining of hnRNPD was median RFS = 22 months as compared to 69 months for the patients showing low scores for nuclear hnRNPD immunostaining and absence of node (p = 0.028). (C)Evaluation of nuclear hnRNPD as a diagnostic marker for distinguishing oral dysplasia and OSCCs from normal oral tissues. Panel shows ROC analysis for (i) Oral dysplasia vs. normal and (ii) OSCCs vs. normal oral tissues.